Workflow
Cardiff Oncology(CRDF)
icon
Search documents
Cardiff Oncology (CRDF) FY Conference Transcript
2023-01-18 19:30
Cardiff Oncology (CRDF) FY Conference January 18, 2023 01:30 PM ET Speaker0 All right. Good afternoon, everyone. Welcome to B. Riley Securities Oncology Conference and listening to our fireside chat. I'm Yuan Zhi, a healthcare equity research analyst at B. Riley Securities. Today, it's my great pleasure to have Mark Erlander, CEO of Cardiff Oncology. Thank you for joining us today. I want to focus today's discussion on your clinical trial of colorectal cancer and pancreatic cancer. But Mark, can you give us ...
Cardiff Oncology (CRDF) Investor Presentation - Slideshow
2022-11-04 16:04
The Onvansertib Opportunity Company Overview Forward-looking statements Certain statements in this presentation are FORWARD-LOOKING within the meaning of the Private Securities Litigation Reform Act of 1995. These statements may be identified by the use of words such as "anticipate," "believe," "forecast," "estimated" and "intend" or other similar terms or expressions that concern our expectations, strategy, plans or intentions. These forward-looking statements are based on our current expectations and actu ...
Cardiff Oncology(CRDF) - 2022 Q3 - Quarterly Report
2022-11-02 16:00
Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 10-Q (Mark One) ☒ QUARTERLY REPORT UNDER SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2022 ☐ TRANSITION REPORT UNDER SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to COMMISSION FILE NUMBER 001-35558 CARDIFF ONCOLOGY, INC. (Exact Name of registrant as specified in its charter) Delaware 27-2004382 (State or other j ...
Cardiff Oncology (CRDF) Investor Presentation - Slideshow
2022-09-09 16:18
The Onvansertib Opportunity Company Overview Forward-Looking Statements Certain statements in this presentation are FORWARD-LOOKING within the meaning of the Private Securities Litigation Reform Act of 1995. These statements may be identified by the use of words such as "anticipate," "believe," "forecast," "estimated" and "intend" or other similar terms or expressions that concern our expectations, strategy, plans or intentions. These forward-looking statements are based on our current expectations and actu ...
Cardiff Oncology(CRDF) - 2022 Q2 - Quarterly Report
2022-08-03 16:00
Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 10-Q (Mark One) ☒ QUARTERLY REPORT UNDER SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2022 ☐ TRANSITION REPORT UNDER SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to COMMISSION FILE NUMBER 001-35558 CARDIFF ONCOLOGY, INC. (Exact Name of registrant as specified in its charter) Delaware 27-2004382 (State or other jurisd ...
Cardiff Oncology (CRDF) Investor presentations - Slideshow
2022-05-25 15:50
The Onvansertib Opportunity Company Overview Forward-Looking Statements Certain statements in this presentation are FORWARD-LOOKING within the meaning of the Private Securities Litigation Reform Act of 1995. These statements may be identified by the use of words such as "anticipate," "believe," "forecast," "estimated" and "intend" or other similar terms or expressions that concern our expectations, strategy, plans or intentions. These forward-looking statements are based on our current expectations and actu ...
Cardiff Oncology(CRDF) - 2022 Q1 - Quarterly Report
2022-05-04 16:00
Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 10-Q (Mark One) ☒ QUARTERLY REPORT UNDER SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2022 ☐ TRANSITION REPORT UNDER SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to COMMISSION FILE NUMBER 001-35558 CARDIFF ONCOLOGY, INC. (Exact Name of registrant as specified in its charter) Delaware 27-2004382 (State or other juris ...
Cardiff Oncology (CRDF) Investor Presentation - Slideshow
2022-03-31 18:43
The Onvansertib Opportunity Company Overview Forward-Looking Statements Certain statements in this presentation are FORWARD-LOOKING within the meaning of the Private Securities Litigation Reform Act of 1995. These statements may be identified by the use of words such as "anticipate," "believe," "forecast," "estimated" and "intend" or other similar terms or expressions that concern our expectations, strategy, plans or intentions. These forward-looking statements are based on our current expectations and actu ...
Cardiff Oncology(CRDF) - 2021 Q4 - Annual Report
2022-02-23 16:00
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 10-K (Mark One) ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2021 ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the Transition Period from to Commission File Number: 001-35558 CARDIFF ONCOLOGY, INC. (Exact name of registrant as specified in its charter) Delaware 27-2004382 (State or other jurisdiction of ...
Cardiff Oncology (CRDF) - Investor Presentation slideshow
2022-01-31 17:35
The Onvansertib Opportunity Company Overview Forward-Looking Statements Certain statements in this presentation are FORWARD-LOOKING within the meaning of the Private Securities Litigation Reform Act of 1995. These statements may be identified by the use of words such as "anticipate," "believe," "forecast," "estimated" and "intend" or other similar terms or expressions that concern our expectations, strategy, plans or intentions. These forward-looking statements are based on our current expectations and actu ...